IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).

被引：0
|
作者：
Zeidan, Amer Methqal
Platzbecker, Uwe
Santini, Valeria
Fenaux, Pierre
Sekeres, Mikkael A.
Savona, Michael R.
Madanat, Yazan F.
Diez-Campelo, Maria
Valcarcel, David
Illmer, Thomas
Jonasova, Anna
Belohlavkova, Petra
Sherman, Laurie Jill
Berry, Tymara
Dougherty, Souria
Shah, Sheetal
Sun, Libo
Wan, Ying
Huang, Fei
Komrokji, Rami S.
机构：
[1] Yale Univ, Dept Internal Med, Yale Sch Med, New Haven, CT USA
[2] Yale Univ, Yale Canc Ctr, New Haven, CT USA
[3] Leipzig Univ Hosp, Dept Hematol Cellular Therapy & Hemostaseol, Leipzig, Germany
[4] Univ Florence, Azienda Osped Univ Careggi, MDS Unit, Florence, Italy
[5] Univ Paris 07, Hop St Louis, Paris, France
[6] Univ Miami, Div Hematol, Sylvester Comprehens Canc Ctr, Miami, FL USA
[7] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Med Ctr, Nashville, TN USA
[8] UT SouthWestern Med Ctr, Simmons Comprehens Canc Ctr, Dallas, TX USA
[9] Univ Hosp Salamanca, Hematol Dept, Salamanca, Spain
[10] Hosp Univ Vall dHebron, Hematol Dept, Barcelona, Spain
[11] Hematol Private Practice, Dresden, Germany
[12] Gen Hosp, Med Dept 1, Hematol, Prague, Czech Republic
[13] Charles Univ Hosp, Dept Internal Med Haematol 4, Hradec Kralove, Czech Republic
[14] Geron Corp, Foster City, CA USA
[15] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7004
引用
收藏
页数：1
相关论文
共 32 条
  • [1] Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)
    Platzbecker, Uwe
    Komrokji, Rami S.
    Zeidan, Amer M.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Savona, Michael R.
    Madanat, Yazan F.
    Jonasova, Anna
    Illmer, Thomas
    Sherman, Laurie
    Berry, Tymara
    Riggs, Jennifer
    Xia, Qi
    Navada, Shyamala
    Wan, Ying
    Huang, Fei
    Feller, Faye M.
    Santini, Valeria
    BLOOD, 2023, 142
  • [2] Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study
    Platzbecker, Uwe
    Komrokji, Rami S.
    Fenaux, Pierre
    Zeidan, Amer M.
    Sekeres, Mikkael A.
    Savona, Michael Robert
    Madanat, Yazan F.
    Santini, Valeria
    Van Eygen, Koen
    Raza, Azra
    Germing, Ulrich
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Sun, Libo
    Huang, Fei
    Feller, Faye
    Wan, Ying
    Ikin, Annat
    Sherman, Laurie
    BLOOD, 2022, 140 : 1106 - 1108
  • [3] Disease Modifying Activity of Imetelstat in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase
    Santini, Valeria
    Platzbecker, Uwe
    Fenaux, Pierre
    Sekeres, Mikkael
    Savona, Michael
    Madanat, Yazan
    Diez-Campelo, Maria
    Valcarcel-Ferreiras, David
    Illmer, Thomas
    Jonasova, Anna
    Belohlavkova, Petra
    Sherman, Laurie
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Xia, Qi
    Peng, Lixian
    Sun, Libo
    Wan, Ying
    Huang, Fei
    Ikin, Annat
    Navada, Shyamala
    Feller, Faye
    Zeidan, Amer
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S373 - S374
  • [4] Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase III
    Platzbecker, Uwe
    Santini, Valeria
    Fenaux, Pierre
    Sekeres, Mikkael
    Savona, Michael
    Madanat, Yazan
    Diez-Campelo, Maria
    Valcarcel-Ferreiras, David
    Illmer, Thomas
    Jonasova, Anna
    Belohlavkova, Petra
    Sherman, Laurie
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Xia, Qi
    Peng, Lixian
    Sun, Libo
    Wang, Ying
    Huang, Fei
    Ikin, Annat
    Navada, Shyamala
    Feller, Faye
    Komrokji, Rami
    Zeidan, Amer
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S371 - S371
  • [5] Treatment With Imetelstat Provides Durable Transfusion Independence in Heavily Transfused Non-Del(5q) Lower-Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 12 - 14
  • [6] Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs Placebo in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents
    Sekeres, Mikkael
    Santini, Valeria
    Diez-Campelo, Maria
    Komrokji, Rami
    Fenaux, Pierre
    Savona, Michael
    Madanat, Yazan
    Valcarcel-Ferreiras, David
    Illmer, Thomas
    Jonasova, Anna
    Belohlavkova, Petra
    Regnault, Antoine
    Creel, Kristin
    Sengupta, Nishan
    Sherman, Laurie
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Xia, Qi
    Sun, Libo
    Wan, Ying
    Huang, Fei
    Ikin, Annat
    Navada, Shymala
    Feller, Faye
    Zeidan, Amer
    Platzbecker, Uwe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S373 - S373
  • [7] IMPACT OF IMETELSTAT TREATMENT ON PROS AND HEALTH CARE RESOURCE UTILIZATION IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/ REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS: IMERGE PHASE 3 TRIAL
    Sekeres, M.
    Santini, V
    Diez-Campelo, M.
    Komrokji, R.
    Fenaux, P.
    Savona, M.
    Madanat, Y.
    Valcarcel-Ferreiras, D.
    Illmer, T.
    Jonasova, A.
    Belohlavkova, P.
    Regnault, A.
    Creel, K.
    Sengupta, N.
    Sherman, L.
    Berry, T.
    Dougherty, S.
    Shah, S.
    Xia, Q.
    Sun, L.
    Wan, Y.
    Huang, F.
    Ikin, A.
    Navada, S.
    Feller, F.
    Zeidan, A.
    Platzbecker, U.
    VALUE IN HEALTH, 2023, 26 (12) : S28 - S29
  • [8] On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)
    Santini, Valeria
    Fenaux, Pierre
    Van Eygen, Koen
    Raza, Azra
    Germing, Ulrich
    Font, Patricia
    Diez-Campelo, Maria
    Thepot, Sylvain
    Vellenga, Edo
    Patnaik, Mrinal M.
    Jang, Jun Ho
    Sherman, Laurie
    Berry, Tymara
    Feller, Faye
    Dougherty, Souria
    Sun, Libo
    Wan, Ying
    Rizo, Aleksandra
    Huang, Fei
    Platzbecker, Uwe
    BLOOD, 2021, 138
  • [9] Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
    Santini, Valeria
    Almeida, Antonio
    Giagounidis, Aristoteles
    Groepper, Stefanie
    Jonasova, Anna
    Vey, Norbert
    Mufti, Ghulam J.
    Buckstein, Rena
    Mittelman, Moshe
    Platzbecker, Uwe
    Shpilberg, Ofer
    Ram, Ron
    del Canizo, Consuelo
    Gattermann, Norbert
    Ozawa, Keiya
    Risueno, Alberto
    MacBeth, Kyle J.
    Zhong, Jianhua
    Seguy, Francis
    Hoenekopp, Albert
    Beach, C. L.
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2988 - +
  • [10] Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence ( RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study
    Komrokji, Rami S.
    Santini, Valeria
    Fenaux, Pierre
    Savona, Michael R.
    Madanat, Yazan F.
    Berry, Tymara
    Sherman, Laurie
    Navada, Shyamala
    Feller, Faye M.
    Sun, Libo
    Xia, Qi
    Wan, Ying
    Huang, Fei
    Zeidan, Amer M.
    Platzbecker, Uwe
    BLOOD, 2023, 142
1234